Compare PLRX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLRX | PCRX |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9M | 1.0B |
| IPO Year | 2020 | 2010 |
| Metric | PLRX | PCRX |
|---|---|---|
| Price | $1.28 | $22.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $2.67 | ★ $37.60 |
| AVG Volume (30 Days) | 533.4K | ★ 773.2K |
| Earning Date | 03-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.97 | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $9.77 |
| Revenue Next Year | N/A | $9.71 |
| P/E Ratio | ★ N/A | $141.53 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $1.09 | $18.80 |
| 52 Week High | $1.95 | $27.99 |
| Indicator | PLRX | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 46.76 |
| Support Level | $1.12 | $20.09 |
| Resistance Level | $1.36 | $23.82 |
| Average True Range (ATR) | 0.07 | 1.06 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 29.27 | 32.59 |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.